Today: 27 June 2026
Barclays share price steadies after fresh buyback disclosure as UK inflation looms
17 February 2026
1 min read

Barclays share price steadies after fresh buyback disclosure as UK inflation looms

London, Feb 17, 2026, 08:10 GMT — Regular session trading underway.

  • Barclays kicked off the session up roughly 0.2%, following fresh details on its latest round of share buybacks.
  • UK banks are attempting a comeback after last week’s sharp slide, which was fueled by AI-related risk concerns.
  • UK inflation numbers hit Feb. 18. Next up, the Bank of England’s rate decision in March is on traders’ radar.

Barclays kicked off Tuesday trading at 462.05 pence, up roughly 0.2% from Monday’s finish, after the bank disclosed it had repurchased 3.23 million shares for cancellation under its ongoing buyback. According to the filing, the shares changed hands at a volume-weighted average of 464.3338 pence.

Why it matters now: UK banks have swung around lately, with buybacks offering a brief cushion for investors looking for new economic cues. Monday saw Barclays up 1.5% and NatWest climbing 4.7%. The sector managed a rebound after just logging its steepest weekly loss since late March 2025, a drop triggered by artificial intelligence concerns rattling the market.

Across Europe, sentiment flipped: bank and insurance shares took the lead as the “AI scare trade” lost steam. “There is a growing sense that fears about AI … are overdone,” said Kathleen Brooks, research director at XTB. Reuters

Most of the heavy lifting right now is being done by rate expectations. According to a Reuters poll out Monday, the majority of economists predict the Bank of England will deliver a 25 basis point rate cut, bringing it down to 3.50% on March 19—this after February’s narrow 5-4 split left rates at 3.75%. “We stick to our call for the next Bank Rate cut to come in March,” Sanjay Raja, Deutsche Bank’s chief UK economist, told Reuters. James Rossiter at TD Securities put it this way: inflation probably “around the 2.5% mark” by the end of the year. Reuters

Wednesday at 0700 GMT brings January’s UK consumer inflation numbers. Depending on which way the data goes, rate-cut bets could shift—taking bank stocks with them.

January retail sales land at 0700 GMT on Feb. 20, just two days on. The print offers a glimpse into household demand and credit trends.

Barclays rolled out fresh targets last week after a 12% jump in 2025 profit and an upgrade to its return ambitions. CEO C.S. Venkatakrishnan pledged the bank would hand back over 15 billion pounds to shareholders from 2026 to 2028. Citi analysts, though, called the new goals “somewhat muted” and pointed to stiff competition in the U.S. consumer segment. Reuters

The road isn’t straight. If inflation comes in hotter, rate cuts might get delayed, which could knock rate-sensitive banks. And if another risk-off selloff arrives, that sector could tumble again—especially after its sharp rally earlier this month.

Barclays traders are now eyeing the UK inflation figures set for release at 0700 GMT on Wednesday. The Bank of England’s next call on the Bank Rate lands March 19.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Telix Pharmaceuticals and Two Australian Insider-Led Growth Stocks Highlighted
    June 27, 2026, 11:07 AM EDT. Telix Pharmaceuticals (ASX:TLX), a A$5.2 billion biopharmaceutical firm specializing in radiopharmaceuticals for cancer imaging and treatment, draws growth-focused investors despite ongoing losses. The company reported US$621.9 million revenue from Precision Medicine and relies heavily on its oncology pipeline with products like Illuccix and late-stage candidates TLX591 and TLX101. Key risks include high R&D costs, regulatory scrutiny, pricing pressures, and trial dependencies. Also featured are two Australian insider-led growth stocks identified by the Fast Growing Stocks With High Insider Ownership screener, highlighting firms with aligned management-shareholder interests amid mixed inflation and cautious central bank policies.

Latest articles

Generate Biomedicines stock ends week back above IPO price as volume jumps

Generate Biomedicines stock ends week back above IPO price as volume jumps

27 June 2026
Generate Biomedicines (NASDAQ:GENB) surged 13.7% since June 18 to close Friday at $16.47—above its $16 IPO price—with heavy volume and a $2.11B market cap, as investors weigh its $516.6M cash pile, ongoing clinical trial risks, and lack of product revenue, while sector momentum lifts biotech stocks.
Snowflake (NYSE:SNOW) finishes up for the week after Russell rebalance trading

Snowflake (NYSE:SNOW) finishes up for the week after Russell rebalance trading

27 June 2026
Snowflake Inc (NYSE:SNOW) surged 9.65% to $248.96 on Friday with trading volume five times the weekly average, driven by FTSE Russell’s U.S. index reconstitution, turning a negative week into a 7.2% gain since June 18, as investors await whether the stock can hold above its previous $225.95–$230.41 range when index-driven liquidity fades next week.
GameStop (NYSE:GME) holds close to cash levels after company guides for $600 million in EBITDA

GameStop (NYSE:GME) holds close to cash levels after company guides for $600 million in EBITDA

27 June 2026
GameStop surged 3.57% to $21.76 and jumped after hours as it forecast FY2026 adjusted EBITDA above $600 million, nearly doubling from 2025; with a $9.76 billion market cap now close to its $9.7 billion in cash, securities, digital assets, and collateral, investors are weighing whether GameStop’s cash-rich balance sheet can support equity while Ryan Cohen pursues an eBay bid.
ImmunityBio (NASDAQ:IBRX) trades after post-Russell spike with 46% more volume

ImmunityBio (NASDAQ:IBRX) trades after post-Russell spike with 46% more volume

27 June 2026
ImmunityBio surged 11.8% to $8.71 on Friday with volume tripling its average, as Russell index reconstitution took effect; Monday’s trading will reveal if demand persists or if the spike was driven by index flows, with no imminent company events and recent insider selling accounting for just 0.06% of Friday’s volume.
Uber stock: Tuesday test looms after Uber Eats targets $1 billion boost in Europe
Previous Story

Uber stock: Tuesday test looms after Uber Eats targets $1 billion boost in Europe

GE stock price rises as Morgan Stanley starts GE Aerospace; American Airlines keeps CFM LEAP engines
Next Story

GE stock price rises as Morgan Stanley starts GE Aerospace; American Airlines keeps CFM LEAP engines

Go toTop